# Emergent BioSolutions Inc.: Form 10-Q for the period ended Sep 30, 2021

- Company: [Emergent BioSolutions Inc.](/companies/ebs.md) (CIK 1367644)
- Form: 10-Q
- Filed: 2021-11-05
- Accepted by EDGAR: Nov 5, 2021, 16:51 ET
- Period: 2021-09-30
- Accession: 0001367644-21-000137
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1367644/000136764421000137/ebs-20210930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1367644/000136764421000137/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2021-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2021-07-01 to 2021-09-30 | $329.0m | us-gaap:Revenues |
| Revenue | 9 months, 2021-01-01 to 2021-09-30 | $1.07bn | us-gaap:Revenues |
| Research and development | 3 months, 2021-07-01 to 2021-09-30 | $49.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2021-01-01 to 2021-09-30 | $151.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2021-07-01 to 2021-09-30 | $82.1m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2021-01-01 to 2021-09-30 | $254.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2021-07-01 to 2021-09-30 | −$34.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2021-01-01 to 2021-09-30 | $75.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2021-07-01 to 2021-09-30 | $8.4m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2021-01-01 to 2021-09-30 | $25.5m | us-gaap:InterestExpense |
| Income tax | 3 months, 2021-07-01 to 2021-09-30 | −$12.8m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2021-01-01 to 2021-09-30 | $5.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2021-07-01 to 2021-09-30 | −$32.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2021-01-01 to 2021-09-30 | $41.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.61 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2021-01-01 to 2021-09-30 | $0.77 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2021-07-01 to 2021-09-30 | −$0.61 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2021-01-01 to 2021-09-30 | $0.78 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2021-07-01 to 2021-09-30 | 53,700,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2021-01-01 to 2021-09-30 | 54,300,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2021-01-01 to 2021-09-30 | −$7.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2021-01-01 to 2021-09-30 | $178.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2021-09-30 | $403.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2021-09-30 | $1.11bn | us-gaap:AssetsCurrent |
| Total assets | at 2021-09-30 | $2.87bn | us-gaap:Assets |
| Current liabilities | at 2021-09-30 | $365.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2021-09-30 | $1.34bn | us-gaap:Liabilities |
| Long-term debt | at 2021-09-30 | $817.3m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2021-09-30 | $31.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2021-09-30 | $1.52bn | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1367644/000136764421000137/ebs-20210930.htm

Filed Nov 5, 2021.
Source: SEC EDGAR, the filing index for accession 0001367644-21-000137. Last ingested by Listed: Nov 4, 2026, 16:51 ET. No prices; not investment advice.
